Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2-8-2021

Treatment of patients with chronic pruritus of unknown origin with
dupilumab
Jiehyun Jeon
Fang Wang
Asima Badic
Brian S Kim

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Journal of Dermatological Treatment

ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/ijdt20

Treatment of patients with chronic pruritus of
unknown origin with dupilumab
Jiehyun Jeon, Fang Wang, Asima Badic & Brian S. Kim
To cite this article: Jiehyun Jeon, Fang Wang, Asima Badic & Brian S. Kim (2021): Treatment
of patients with chronic pruritus of unknown origin with dupilumab, Journal of Dermatological
Treatment, DOI: 10.1080/09546634.2021.1880542
To link to this article: https://doi.org/10.1080/09546634.2021.1880542

© 2021 The Author(s). Published with
license by Taylor & Francis Group, LLC
Published online: 08 Feb 2021.

Submit your article to this journal

Article views: 1680

View related articles

View Crossmark data

Citing articles: 5 View citing articles

Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=ijdt20

JOURNAL OF DERMATOLOGICAL TREATMENT
https://doi.org/10.1080/09546634.2021.1880542

SHORT REPORT

Treatment of patients with chronic pruritus of unknown origin with dupilumab
Jiehyun Jeona,b,c

, Fang Wanga,b,d, Asima Badica,b and Brian S. Kima,b,e,f

a

Division of Dermatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA; bCenter for the Study of
Itch and Sensory Disorders, Washington University School of Medicine, St. Louis, MO, USA; cDepartment of Dermatology, College of
Medicine, Korea University, Seoul, Korea; dDepartment of Dermatology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou,
Guangdong, China; eDepartment of Anesthesiology, Washington University School of Medicine, St. Louis, MO, USA; fDepartment of
Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA
ABSTRACT

ARTICLE HISTORY

Background: Chronic pruritus of unknown origin (CPUO) is a highly debilitating disease that lacks
effective treatments. This study explores a new therapeutic strategy with dupilumab.
Objectives: To examine whether patients with CPUO demonstrate clinical response to dupilumab.
Patients and methods: This is a retrospective case series examining all patients with CPUO who
were treated with dupilumab from March 2017 to December 2019 at a tertiary referral clinic at
Washington University School of Medicine in St. Louis, MO. Numerical rating scale (NRS) itch score
changes over time were recorded and analyzed.
Results: Fifteen patients (67% women; mean [SD] age, 68.7 [12.6] years [range, 42–88 years]) were
included in the analysis. All patients had a diagnosis of CPUO for a mean [SD] 2.6 [2.8] years. The
median [IQR] pruritus NRS itch score before dupilumab injection was 8 [8–10] and the final median
[IQR] NRS itch score was 1 [0–2.5]. The mean [SD] reduction in the NRS itch score was 7.0 [1.9].
Dupilumab was well tolerated with one report of mild injection site reaction that was self-resolving.
Conclusion: This study suggests that dupilumab may be an effective treatment for patients with
CPUO and supports the design of future randomized placebo-controlled trials to prove its efficacy.
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Introduction
Classically, chronic pruritus has been viewed as a symptom of a
primary dermatologic or systemic medical disorder. Thus, treatments have focused predominantly on the underlying disease
rather than the symptom itself. However, it is increasingly recognized that many forms of itch can arise in the absence of a
well-defined rash or medical condition. In this context, chronic
pruritus of unknown origin (CPUO) is one such disorder for
which there is no single FDA-approved treatment (1,2).
CPUO is a relatively recently recognized entity that presents
with chronic pruritus for greater than 6 weeks without a defined
causative underlying medical condition. Although patients with
CPUO can present with excoriations and eczematous lesions in the
skin, these findings are considered secondary changes. Further,
recent studies suggest that both local and systemic type 2 inflammation underlie CPUO (3) and that blocking the activity of the
type 2 cytokines interleukin (IL)-4 and IL-13 on sensory neurons
may act to alleviate itch by broadly suppressing neural hypersensitivity (4). Based on these findings, we report our experience with
dupilumab (anti-IL-4Ra monoclonal antibody [mAb]) in patients
with CPUO in a retrospective observational fashion.

Methods
The patients were diagnosed with CPUO according to a recently
published set of consensus recommendations (1). The numerical
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rating scale (NRS) itch score is a single-question assessment tool
measured over the prior 24 h with a scale of 0 (no itch) to 10
(worst imaginable itch) where itch is typically stratified between
0–3 (mild), 4–6 (moderate), and 7 (severe).
This retrospective case series had the following inclusion criteria: (1) chronic pruritus >6 weeks duration, (2) baseline NRS
itch score of 7 (severe), (3) consecutive recruitment between
March 2017 to December 2019, and (4) dupilumab (600 mg subcutaneous [SC] injection followed by 300 mg SC biweekly) treatment. Exclusion criteria included: (1) any primary dermatologic
disorder that could account for the pruritus, and (2) any lab or
radiologic abnormality based on recent consensus recommendations that could account of their itch (1). Further, if patients met
diagnostic criteria for atopic dermatitis or had evidence of prurigo nodularis or any other defined dermatitis, they were
excluded. Recruitment was made by non-selectively enrolling all
patients meeting the above-mentioned criteria regardless of the
treatment results and concomitant diseases.
Given that this is a case series, no concomitant medications
were stopped, and the use of emollients and topical steroids
was allowed. Treatment response was assessed using change in
NRS itch score from prior to treatment with dupilumab to the
most current NRS itch score at time of data analysis.
Differences were considered statistically significant for a twotailed p < .05. This study was approved by the Institutional
Review Board of Washington University in St. Louis (Missouri,
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Table 1. Patient demographics, NRS scores, and follow-up time of improvement of patients.
Number (n ¼ 15)

Characteristics
Sex, No. (%)
Age at diagnosis (years), mean ± S.D.
Duration of itch (years), mean ± S.D.
Initial NRS, median [IQR]
Final NRS, median [IQR]
NRS reduction, mean ± S.D.
Follow-up period of dupilumab treatment of patients (months), median [IQR]

M : F ¼ 6 (33) : 9 (67)
68.7 ± 12.6
2.6 ± 2.8
8 [8  10]
1 [0  2.5]
7.0 ± 1.9
19 [10  26]

USA) and followed the tenets of the Declaration of Helsinki (IRB
ID No. 201412117 and 201605144).

Results
A total of 15 patients were evaluated based on our inclusion/
exclusion criteria. The mean [SD] age was 68.7 [12.6] years and
9/15 were female. The mean [SD] duration of itch prior to presentation was 2.6 [2.8] years. The median [interquartile range,
IQR] time from baseline NRS itch score to the primary endpoint
NRS itch analysis was 19 [10–26] months. All baseline characteristics are presented in Table 1.
All of the 15 subjects experienced marked reduction in pruritus symptoms as measured by the NRS itch score from baseline
(Figure 1). The median [IQR] baseline 24-h NRS itch score was 8
[8–10] with a final NRS itch score of 1 [0–2.5]. The mean [SD]
reduction in the NRS itch score was 7.0 [1.9] (Table 1). Given
that these patients were evaluated during the course of routine
care, systematic daily assessment of itch improvement over time
was not acquired from all patients. Notwithstanding this, two of
the subjects (Patient 2 and Patient 15) reported notable
improvement of itch within 72 h of their first injection of dupilumab. Interestingly, one subject (Patient 9) reported delayed
improvement of pruritus between 6 and 10 months after initiating treatment. Four patients (Patients 3, 4, 5, and 13) were followed over 24 months and the efficacy of dupilumab was
observed consistently throughout this time period (Figure 1). All
patients did not have rash at baseline, however, some patients
did exhibit mild or moderate excoriations on the back (Figure
2(A)) that resolved with treatment (Figure 2(B)). One patient
experienced a mild injection site reaction that then improved
and no other adverse events (AEs) were observed such as conjunctivitis or facial dermatitis. Collectively, these findings suggest
that dupilumab may be an effective and safe therapeutic for
patients with CPUO. However, prospective randomized placebocontrolled clinical trials are needed to prove both efficacy and
safety for this indication.

Discussion
In the absence of US Food and Drug Administration-approved
therapies for CPUO, a wide range of traditional therapies have
been employed including oral and topical corticosteroids,
phototherapy, neuromodulators like gabapentin, and steroidsparing immunosuppressants like azathioprine (5). However,
there are currently no universally effective treatments and data
on newer agents are limited.
New advances in neuroimmunology have revealed that targeting cytokines at the immune-sensory neuron interface represents a novel therapeutic strategy. The first pruritogenic
cytokine, IL-31, is now a biologic target for nemolizumab (antiIL-31RA mAb) in atopic dermatitis and prurigo nodularis (6,7),

Figure 1. Numerical Rating Scale (NRS) Itch Score of Patients over Time.
Improvement of NRS Itch Score with Dupilumab Treatment in 15 Patients with
CPUO over Time (p < .0001, Wilcoxon signed-rank nonparametric test).

and has recently been shown to be elevated in the sera of
patients with CPUO (8). In addition to IL-31, recent advances in
our understanding of IL-4 and IL-13 and downstream Janus kinase (JAK) on sensory neurons in itch (4) have advanced a paradigm in which JAK inhibitors, in addition to their antiinflammatory properties, may have neuromodulatory mechanisms of action in itch. Indeed, recent proof-of-concept studies
have suggested anti-itch efficacy of both the JAK inhibitor tofacitinib and dupilumab in CPUO (9,10). Thus, the current study
lends further support for pharmacologic disruption of cytokineneural interactions as a potential treatment strategy for CPUO.
However, not all agents investigated in clinical studies for
CPUO have demonstrated success. A recent proof-of-concept
phase 2a study of apremilast, a phosphodiesterase 4 inhibitor,
demonstrated poor tolerability and could not be evaluated for
efficacy in CPUO (11). Additionally, the first randomized placebo-controlled trial in CPUO with the neurokinin 1 receptor
antagonist serlopitant did not demonstrate efficacy over placebo in phase 2 studies (12) and also failed to show efficacy in
phase 3 studies in prurigo nodularis (13). Collectively, these findings suggest that certain pathways may be more suitable as a
therapeutic target in CPUO.
Given that our study is a consecutive case series and these
patients were undergoing routine care, there are limitations.
The study was not randomized, unblinded, and some variables
could not be controlled like concomitant medications and
assessment timepoints. Notwithstanding these limitations, our
findings coupled with other recent studies (14,15), provide a scientific premise to support a proper evaluation of the efficacy of
dupilumab for CPUO.

Conclusions
Dupilumab may have anti-itch efficacy in CPUO and was well
tolerated in 15 patients with CPUO. Future randomized doubleblind placebo-controlled trials are warranted to determine the
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Figure 2. Representative Clinical Photographs of a Patient with CPUO Treated with Dupilumab. (A) Excoriations on Back Prior to Dupilumab Treatment. (B) Visibly
Cleared Back with Faint Erythema After Treatment for 4 Months with Dupilumab.

efficacy of dupilumab in this highly debilitating medical condition which currently lacks effective therapies.
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